The effect of RGD-containing peptides was further verified by
immunoblot analysis for α-SMA. In control, untreated keratocyte
cultures there was no detectable α-SMA protein (
Fig. 4 A, lane 1), whereas cultures treated with 1 ng/ml TGF
β for
3 days showed staining of a prominent protein band that migrated at
approximately 45 kDa (
Fig. 4A , lane 2), consistent with smooth muscle
actin. Cultures treated with GRGDNP (50 μM) in combination with
TGF
β (1 ng/ml) showed no detectable levels of α-SMA
protein (
Fig. 4A , lane 3), similar to that observed in the untreated
control cultures. Cultures treated with the control peptide, GRADSP at
100 μM (
Fig. 4A , lane 4), showed a level of expression of α-SMA
similar to that observed in cultures treated with TGF
β alone. Northern blot analysis of RNA isolated from parallel cultures
showed low-level binding of the α-SMA cDNA probe to a 1.7-kb RNA
species of a size consistent with that expected for rabbit α-SMA
(
Fig. 4B , lane 1). When keratocytes were treated with
TGF
β alone (1 ng/ml) for 3 days, there was a marked
increase in the level of binding of the α-SMA cDNA (
Fig. 4B , lane 2),
comparable to the level of binding detected in RNA from serum-cultured
keratocytes (
Fig. 4B , lane 4). When keratocytes were cotreated with
GRGDdSP (50 μM) and TGF
β (1 ng/ml), binding was
substantially reduced to levels observed in control, untreated cells.
These findings suggest that the upregulation of α-SMA mRNA induced by
TGF
β is blocked when the binding of fibronectin to
surface membrane receptors is inhibited and that the decrease inα
-SMA protein observed after GRGDdSP treatment may be caused by a
block in the upregulation of α-SMA message by TGF
β.
However, because the isoforms of actin show considerable sequence
homology, further work is necessary to demonstrate gene regulation at
the transcriptional level.